Astria Therapeutics, Inc.ATXSEarnings & Financial Report
Astria Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing novel targeted therapies for rare hematological and allergic diseases with high unmet medical needs. Its core pipeline includes drug candidates designed to address life-threatening immune-mediated conditions, serving patient populations across North America and other global markets with limited existing treatment options.
ATXS Q3 FY2025 Key Financial Metrics
Revenue
$706.0K
Gross Profit
N/A
Operating Profit
$-34.1M
Net Profit
$-31.6M
Gross Margin
N/A
Operating Margin
-4830.6%
Net Margin
-4482.0%
YoY Growth
N/A
EPS
$-0.55
Astria Therapeutics, Inc. Q3 FY2025 Financial Summary
Astria Therapeutics, Inc. reported revenue of $706.0K for Q3 FY2025, with a net profit of $-31.6M (down 29.0% YoY) (-4482.0% margin).
Key Financial Metrics
| Total Revenue | $706.0K |
|---|---|
| Net Profit | $-31.6M |
| Gross Margin | N/A |
| Operating Margin | -4830.6% |
| Report Period | Q3 FY2025 |
Astria Therapeutics, Inc. Quarterly Revenue & Net Profit History
Astria Therapeutics, Inc. results over the last 2 reported quarters, including revenue, net profit and year-over-year growth.
| Quarter | Revenue | Revenue YoY | Net Profit | Net Margin |
|---|---|---|---|---|
| Q3 FY2025 | $706.0K | — | $-31.6M | -4482.0% |
| Q3 FY2024 | $0 | — | $-24.5M | N/A |
Income Statement
| Q3 2024 | Q3 2025 | |
|---|---|---|
| Revenue | $0 | $706000 |
| YoY Growth | N/A | N/A |
Balance Sheet
| Q3 2024 | Q3 2025 | |
|---|---|---|
| Assets | $361.6M | $271.9M |
| Liabilities | $20.0M | $38.6M |
| Equity | $341.7M | $233.3M |
Cash Flow
| Q3 2024 | Q3 2025 | |
|---|---|---|
| Operating CF | $-28.0M | $-32.3M |